Physician profile
Pingfeng Du
NPI 1285694349
$25,110.39
in general payments reported to CMS, 2019-2025
45 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $898 · 2021: $1,303 · 2022: $828 · 2023: $536 · 2024: $910 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,809.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impedimed, INC. | $18,380.00 | 2019 | |
| Pfizer INC. | $938.32 | 2019-2025 | |
| Amgen INC. | $745.70 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $439.57 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $367.52 | 2019-2025 | |
| Boston Scientific Corporation | $307.30 | 2019-2025 | Cds - Mct/Cem Monitoring, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Amarin Pharma, INC. | $302.32 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $299.90 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.63 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $292.13 | 2020-2025 | Wainua, Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $281.72 | 2019-2025 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $209.53 | 2019-2021 | |
| Tactile Systems Technology INC | $190.05 | 2020-2025 | Nimbl, Flexitouch Plus |
| Kiniksa Pharmaceuticals, LTD. | $177.68 | 2021-2023 | Arcalyst |
| Aop Health US, LLC | $171.85 | 2025 | Rapiblyk |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $168.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $160.99 | 2021-2022 | |
| Esperion Therapeutics, INC. | $129.04 | 2020-2025 | Nexletol |
| Akcea Therapeutics, INC. | $107.31 | 2019-2020 | |
| Novo Nordisk INC | $92.74 | 2021-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $89.99 | 2019-2024 | Mitraclip |
| Alnylam Pharmaceuticals INC. | $82.65 | 2025 | Amvuttra |
| Lilly USA, LLC | $80.82 | 2022-2025 | Zepbound, Mounjaro |
| Kiniksa Pharmaceuticals International, Plc | $77.59 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $77.24 | 2024-2025 | |
| Scpharmaceuticals INC. | $59.62 | 2025 | |
| Itamar Medical INC | $55.89 | 2024-2025 | Watchpatone |
| Cvrx, INC. | $53.60 | 2022-2023 | Barostim Neo System |
| Philips North America LLC | $51.44 | 2023-2025 | (Ck4) Mcot, Extended Holter |
| Regeneron Healthcare Solutions, INC. | $46.80 | 2019-2025 | Evkeeza |
| Edwards Lifesciences Corporation | $45.12 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biotronik INC. | $36.33 | 2025 | Acticor 7 Vr-T Dx |
| Abiomed | $36.25 | 2025 | Invega Sustenna |
| Glaxosmithkline, LLC. | $33.96 | 2025 | Shingrix, Arexvy |
| Irhythm Technologies, INC. | $28.01 | 2022 | |
| Impulse Dynamics (USA) INC. | $23.72 | 2022 | |
| Kestra Medical Technology Services, INC. | $22.49 | 2024 | Assure Wcd |
| Bardy Diagnostics, INC. | $22.00 | 2021 | |
| Medline Industries LP | $21.06 | 2024 | |
| Vifor Pharma, INC. | $20.34 | 2019 | |
| Medtronic Vascular, INC. | $20.28 | 2019 | |
| Chiesi USA, INC. | $19.69 | 2025 | Juxtapid |
| W. L. Gore & Associates, INC. | $19.34 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.98 | 2025 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $14.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pingfeng Du listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.